Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | October 04, 2018 | October 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date October 04, 2018 · Filed October 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,457 |
Reported balance
After 2018-10-04 transaction · row 1
1 source rowRow 1 · 2018-10-04 · Purchase · Acquired 7,100 · Balance 177,457 F1: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. F2: This transaction was executed in multiple trades at prices ranging from $13.90 to $14.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 394,014 |
Reported balance
Holding disclosure · report date 2018-10-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 394,014 F3: These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which the reporting person's spouse serves as the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018.
F2: This transaction was executed in multiple trades at prices ranging from $13.90 to $14.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which the reporting person's spouse serves as the trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2018 Filed Oct 5, 2018 16:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 7,100 | $14.00 | $99,370.18 |
DisclosureSEC source: 0001209191-18-054397 · doc4.xml · nonDerivative · entry 1 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,457 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.90 to $14.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 6,600 | $15.00 | $98,984.82 |
DisclosureSEC source: 0001209191-18-048503 · doc4.xml · nonDerivative · entry 1 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,357 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:55 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 6,250 | $15.97 | $99,812.50 |
DisclosureSEC source: 0001209191-18-047417 · doc4.xml · nonDerivative · entry 1 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,757 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.93 to $16.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 16:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 26,700 | $16.54 | $441,618.00 |
DisclosureSEC source: 0001209191-18-024356 · doc4.xml · nonDerivative · entry 1 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,507 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.23 to $17.06, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 17:03 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 9,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020924 · doc4.xml · nonDerivative · entry 2 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,807 F1 · kind: Pro rata distribution by NST, LLC, of which the reporting person is a member and the sole Manager, in accordance with NST, LLC's Limited Liability Company Operating Agreement. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 17:03 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 94,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020924 · doc4.xml · nonDerivative · entry 1 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NST, LLC Disclosed balance after: 0 F1 · kind: Pro rata distribution by NST, LLC, of which the reporting person is a member and the sole Manager, in accordance with NST, LLC's Limited Liability Company Operating Agreement. F2 · ownership.nature: These shares were held by NST, LLC of which the reporting person is a member and the sole Manager. The reporting person had sole voting and dispositive power over the shares held by NST, LLC. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 19:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142071 · doc4.xml · nonDerivative · entry 5 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,789 F3 · kind: Pro rata distribution by NST, LLC, of which the reporting person is a member, in accordance with NST, LLC's Limited Liability Company Operating Agreement. NST, LLC received 144,153 shares of the issuer's common stock as a liquidating distribution from NeXeption, LLC described in footnotes (1) and (2) above and immediately distributed 50,002 of the shares on a pro rata basis to its members. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 19:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 50,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142071 · doc4.xml · nonDerivative · entry 4 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NST, LLC Disclosed balance after: 94,151 F3 · kind: Pro rata distribution by NST, LLC, of which the reporting person is a member, in accordance with NST, LLC's Limited Liability Company Operating Agreement. NST, LLC received 144,153 shares of the issuer's common stock as a liquidating distribution from NeXeption, LLC described in footnotes (1) and (2) above and immediately distributed 50,002 of the shares on a pro rata basis to its members. F2 · ownership.nature: These shares are held by NST, LLC of which the reporting person is a member and the sole Manager. The reporting person has sole voting and dispositive power over the shares held by NST, LLC. The reporting person disclaims beneficial ownership over the shares held by NST, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 19:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 144,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142071 · doc4.xml · nonDerivative · entry 3 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NST, LLC Disclosed balance after: 144,153 F1 · kind: Liquidating distribution by NeXeption, LLC, of which the reporting person is a member, in accordance with NeXeption, LLC's Limited Liability Company Operating Agreement. The reporting person was also the sole Manager of NeXeption, LLC prior to its liquidation. In prior reports, the reporting person reported beneficial ownership of 521,739 shares of the issuer's common stock held by NeXeption, LLC. The reporting person disclaims beneficial ownership of the shares held by NeXeption, LLC except to the extent of his pecuniary interest therein. F2 · ownership.nature: These shares are held by NST, LLC of which the reporting person is a member and the sole Manager. The reporting person has sole voting and dispositive power over the shares held by NST, LLC. The reporting person disclaims beneficial ownership over the shares held by NST, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 19:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 116,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142071 · doc4.xml · nonDerivative · entry 2 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,999 F1 · kind: Liquidating distribution by NeXeption, LLC, of which the reporting person is a member, in accordance with NeXeption, LLC's Limited Liability Company Operating Agreement. The reporting person was also the sole Manager of NeXeption, LLC prior to its liquidation. In prior reports, the reporting person reported beneficial ownership of 521,739 shares of the issuer's common stock held by NeXeption, LLC. The reporting person disclaims beneficial ownership of the shares held by NeXeption, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 19:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 521,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142071 · doc4.xml · nonDerivative · entry 1 Tullman Stephen A. · CIK 0001654343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NeXeption, LLC Disclosed balance after: 0 F1 · kind: Liquidating distribution by NeXeption, LLC, of which the reporting person is a member, in accordance with NeXeption, LLC's Limited Liability Company Operating Agreement. The reporting person was also the sole Manager of NeXeption, LLC prior to its liquidation. In prior reports, the reporting person reported beneficial ownership of 521,739 shares of the issuer's common stock held by NeXeption, LLC. The reporting person disclaims beneficial ownership of the shares held by NeXeption, LLC except to the extent of his pecuniary interest therein. F1 · ownership.nature: Liquidating distribution by NeXeption, LLC, of which the reporting person is a member, in accordance with NeXeption, LLC's Limited Liability Company Operating Agreement. The reporting person was also the sole Manager of NeXeption, LLC prior to its liquidation. In prior reports, the reporting person reported beneficial ownership of 521,739 shares of the issuer's common stock held by NeXeption, LLC. The reporting person disclaims beneficial ownership of the shares held by NeXeption, LLC except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.